SAB Biotherapeutics is a company that makes special medicine to help people with diseases. They had some trouble because their shares were not worth enough, but they fixed it by making the shares more valuable. Now everything is okay and they can keep making their special medicine. Read from source...

- The article does not mention any potential conflicts of interest or financial ties between the author and SAB Biotherapeutics. This is a major omission that undermines the credibility and objectivity of the article.
- The article uses vague and ambiguous terms to describe SAB's technology, such as "fully human", "multi-targeted", and "high-potency". These terms are not well defined or supported by evidence or data, and may mislead readers into thinking that SAB's product is more effective or superior than it actually is.
- The article relies heavily on the company's press releases and statements to present its achievements and progress, without verifying or cross-checking them with independent sources or experts. This raises questions about the accuracy and reliability of the information presented in the article.